Panacea Biotec's stock rises by 5% as the pentavalent vaccination is introduced in India

15 Dec 2023 , 01:21 PM

EasyFourPol, a fully-liquid pentavalent vaccination based on wP-IPV, has been introduced by the biotechnology business in India. Children are protected against five lethal diseases by the wP-IPV pentavalent vaccine: invasive infections caused by Haemophilus influenza type B, pertussis, polio, tetanus, and diphtheria. Furthermore, the company declared that Panacea Biotec Germany GmbH, its step-down, wholly-owned subsidiary, had registered Valganciclovir 50 mg/mL powder for oral solution in Germany. The deoxynucleoside analogue valganciclovir powder inhibits the DNA polymerase of the cytomegalovirus.

On December 15, early trading saw a 5% spike in the price of Panacea Biotec’s shares. This increase occurred after the business introduced ‘EasyFourPol,’ a totally liquid wP-IPV-based pentavalent vaccination, in India.

‘…….. announced the launch of world’s first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol, in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step down wholly-owned subsidiary,’ according to a news release issued by the business.

The first totally liquid wP-IPV Pentavalent vaccination in history, EasyFourPol shields kids from five fatal illnesses: polio, tetanus, pertussis, diphtheria, and invasive infections brought on by Haemophilus influenza type b.

Valganciclovir Powder, a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor, has been registered by the company’s subsidiary Panacea Biotec Germany GmbH in Germany. It is indicated for two purposes: i) the initial and ongoing treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS); and ii) the prophylaxis of CMV disease in CMV-negative adults and children (from birth to 18 years of age) who have received an organ transplant from a CMV-positive donor.

Apotex Inc., Canada, the company’s strategic partner, helped its material wholly-owned subsidiary Panacea Biotec Pharma Limited provide Paclitaxel protein-bound particles for injectable solution (Albumin-Bound), a generic Abraxane, to the Canadian market in October.

The US Food and Drug Administration made nine observations on a Form 483 about its biologics production facility in Baddi on October 12.

Panacea Biotec is a biotechnology firm that engages in vaccine and pharmaceutical product development, manufacture, sales, distribution, and marketing.

The company started to turn a profit in the quarter that ended in September 2023, posting a net profit of Rs 3.20 crore.

For feedback and suggestions, write to us at [e-mail]